Caplin Point Laboratories Limited Earnings Summary — Q1 FY2027
Caplin Point Reports Strong Q1 FY27 Growth with 20.7% Revenue Increase and Major US Market Momentum
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 10 consecutive quarters.
- Revenue of ₹610 Cr is 19.6% higher year-on-year.
- Revenue has compounded at 14.1% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹177 Cr is 15.8% above the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 18.1% annualised across the period.
- Operating margin stands at 35.0% in Q1 FY2027.
- Operating margin expanded by 13 bps year-on-year.
- Over the last two years operating margin has expanded by 189 bps.
- PBT margin is 36.9%.
- Expense growth of 19.4% remained below revenue growth of 19.6%.
- Operating profit of ₹213 Cr is 20.1% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 82/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 610 | 600 | 543 | 534 | 510 | 502 | 493 | 483 | 459 | 453 |
| Expenses | Stable | 397 | 396 | 353 | 345 | 332 | 334 | 331 | 318 | 307 | 308 |
| Operating Profit | Improving | 213 | 204 | 190 | 189 | 178 | 168 | 162 | 165 | 152 | 145 |
| Operating Margin | Stable | 35.0% | 34.0% | 34.9% | 35.4% | 34.8% | 33.5% | 32.9% | 34.1% | 33.1% | 32.0% |
| Other Income | Improving | 34 | 28 | 34 | 30 | 23 | 26 | 31 | 21 | 19 | 17 |
| Interest | Volatile | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | Improving | 22 | 19 | 19 | 18 | 16 | 17 | 16 | 17 | 16 | 16 |
| Profit Before Tax | Improving | 225 | 213 | 204 | 201 | 184 | 177 | 177 | 168 | 154 | 146 |
| Tax | Improving | 46 | 41 | 38 | 41 | 34 | 31 | 37 | 38 | 29 | 25 |
| Net Profit | Improving | 177 | 170 | 164 | 154 | 153 | 143 | 139 | 131 | 124 | 122 |
| Net Margin | Stable | 29.0% | 28.3% | 30.2% | 28.9% | 29.9% | 28.4% | 28.2% | 27.1% | 27.0% | 26.8% |
Key Takeaways
- Consolidated Total Revenue grew 20.7% YoY to ₹644 Crores, driven by healthy growth in both Emerging Markets and the US.
- US Market revenue surged by 26% YoY to ₹137 Crores, now representing approximately 22% of total geographical composition.
- The company maintains a robust liquidity position with Total Liquid Assets of ₹2,875 Crores and Free Cash Reserves of ₹1,502 Crores.
- EBITDA margins improved to 38.4% compared to 37.7% in Q1 FY26, despite a slight compression in gross margins.
- Caplin Steriles (CSL) owns 60 approved ANDAs, with 38 products already launched in the US market to date.
- Significant capital projects are underway, including a new Oncology API unit in Thervoy and a large OSD facility in Puducherry to double capacity.
- Recommended a Final Dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026.
Management Guidance
Management expects meaningful revenue from non-US regulated markets (Canada, EU, Australia) to begin in FY27/FY28. The company has allocated a total Capex budget of over ₹1,000 Crores, with roughly 50% already nearing completion.
Sentiment Shift
Improving
The transition from a B2B-focused business to a dual B2B/B2C model in the US is showing strong initial results without cannibalizing existing partnerships.
Outlook
Focus remains on backward integration via API units, expanding the injectable pipeline (specifically Pre-Filled Syringes), and scaling own-label launches in the US to 12 more products this fiscal year.
From the Annual Report (Key Quotes)
“Our Q1 performance reflects the consistency of our strategy, the resilience of our business model and the disciplined execution across our expanding portfolio.”
“CSU aims to meaningfully grow market share without erosion of bottom line.”
“The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Caplin Point Laboratories Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.